Journal of Pediatric Urology
Volume 3, Issue 6 , Pages 438-442 , December 2007

Treatment with modified intravesical oxybutynin chloride for neurogenic bladder in children

  • Atsushi Hayashi

      Affiliations

    • Division of Pediatrics and Perinatology, Tottori University Faculty of Medicine, Yonago, Japan
    • ,
  • Motoaki Saito

      Affiliations

    • Division of Molecular Pharmacology, Tottori University Faculty of Medicine, 86 Nishimachi, Yonago 683-8503, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 859 38 6163; fax: +81 859 38 6160.
    • ,
  • Shin-ichi Okada

      Affiliations

    • Division of Pediatrics and Perinatology, Tottori University Faculty of Medicine, Yonago, Japan
    • ,
  • Takuya Hanada

      Affiliations

    • Division of Pediatrics and Perinatology, Tottori University Faculty of Medicine, Yonago, Japan
    • Division of Molecular Pharmacology, Tottori University Faculty of Medicine, 86 Nishimachi, Yonago 683-8503, Japan
    • ,
  • Takeshi Watanabe

      Affiliations

    • Division of Urology, Tottori University Faculty of Medicine, Yonago, Japan
    • ,
  • Keisuke Satoh

      Affiliations

    • Division of Molecular Pharmacology, Tottori University Faculty of Medicine, 86 Nishimachi, Yonago 683-8503, Japan
    • ,
  • Susumu Kanzaki

      Affiliations

    • Division of Pediatrics and Perinatology, Tottori University Faculty of Medicine, Yonago, Japan

Received 27 April 2007 ,Accepted 25 May 2007.

References 

  1. Massad CA, Kogan BA, Trigo-Rocha FE. The pharmacokinetics of intravesical and oral oxybutynin chloride. J Urol. 1992;148:595–597
  2. Buyse G, Waldeck K, Verpoorten C, Bjork H, Casaer P, Andersson K-E. Intravesical oxybutynin for neurogenic bladder dysfunction: less systematic side effects due to reduced first pass metabolism. J Urol. 1998;160:892–896
  3. Brendler CB, Radebaugh LC, Mohler JL. Topical oxybutynin chloride for relaxation of dysfunctional bladders. J Urol. 1989;141:1350–1352
  4. Greenfield SP, Fera M. The use of intravesical oxybutynin chloride in children with neurogenic bladder. J Urol. 1991;146:532–534
  5. Saito M, Tabuchi F, Otsubo K, Miyagawa M. Treatment of overactive bladder with modified intravesical oxybutynin chloride. Neurourol Urodyn. 2000;19:683–688
  6. Saito M, Watanabe T, Tabuchi F, Otsubo K, Satoh K, Miyagawa I. Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience. Int J Urol. 2004;1:592–596
  7. Amark P, Bussman G, Eksborg S. Follow-up of long time treatment with intravesical oxybutynin for neurogenic bladder children. Eur Urol. 1998;34:148–153
  8. Kasabian NG, Vlachiotis JD, Lais A, Klumpp B, Kelly MD, Siroky MB, et al. The use of intravesical oxybutynin chloride in patients with detrusor hyperactivity and detrusor hyperreflexia. J Urol. 1994;151:944–945
  9. Palmer LS, Zebold K, Firlit CF, Kaplan WE. Complications of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population. J Urol. 1997;157:638–640
  10. Reitz A, Schurch B. Intravesical therapy options for neurogenic detrusor overactivity. Spinal Cord. 2004;42:267–272
  11. Yoshida M, Miyamae K, Iwashita H, Otani M, Inadome A. Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging. Urology. 2004;63:17–23
  12. Haberberger R, Scholz R, Kummer W, Kress M. M2-receptor subtype does not mediate muscarine-induced increases in Ca(2+)(i) in nociceptive neurons of rat dorsal root ganglia. J Neurophysiol. 2000;84:1934–1941
  13. Saito M, Kinoshita Y, Satoh I, Shinbori C, Suzuki H, Yamada M, et al. Ability of cyclohexenonic long-chain fatty alcohol to reverse diabetes induced cystopathy in the rats. Eur Urol. 2007;51:479–488
  14. Kim Y, Yoshimura N, Masuda H, de Miguel F, Chancellor MB. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder afferent pathways. Urology. 2005;65:238–242
  15. Weese DL, Roskamp DA, Leach GE, Zimmern PE. Intravesical oxybutynin chloride: experience with 42 patients. Urology. 1993;41:527–530
  16. Mizunaga M, Kaneko S, Miyata M, Taniguchi N, Iuchi H, Hashimoto H, et al. New intravesical oxybutynin hydrochloride used for the treatment of neurogenic bladder dysfunction. Neurourol Urodyn. 1996;15:306–307
  17. Ottolini MC, Shaer CM, Rushdon HG, Majd M, Gonzales EC, Patel KM. Relationship of asymptomatic bacteriuria and renal scarring in children with neurogenic bladders who are practicing clean intermittent self-catheterization. J Urol. 1995;157:368–372

PII: S1477-5131(07)00368-3

doi: 10.1016/j.jpurol.2007.05.007

Journal of Pediatric Urology
Volume 3, Issue 6 , Pages 438-442 , December 2007

Article Tools

* Image Usage & Resolution